Treatment of symptomatic vasospasm with nimodipine.
Over a seven-year period, 130 patients with delayed ischaemia after cerebral aneurysm haemorrhage were treated with intravenous nimodipine. The delay from the last haemorrhage to the appearance of ischaemic symptoms was one to 18 days, and vasospasm was confirmed in most cases. Nimodipine treatment was started within three days of delayed ischaemic deficit (DID) onset, at a low dose increased quickly to 30-45 ug/kg/hr, and reduced gradually over the last day or two of the course. The duration of treatment was one to 27 days. Side effects were minor, and serious complications few. Hypotension occurred in 35 cases. During treatment, there were highly significant improvements in both clinical grade and Glasgow Coma Score. The final outcome was 98 good (Glasgow Outcome Score 1), 18 permanent deficits (eight GOS 2, ten GOS 3), and 14 dead. Ischaemia was directly involved in only half the deaths. These results are much better than the natural history (about 1/3 dead and 1/3 disabled), and a considerable improvement over fluid and hypertensive treatment (17% dead, 29% deficits), calculated from a literature review. Nimodipine is also safer than induced hypertension, especially pre-operatively.
Dorsch
N W
NW
Department of Surgery, Westmead Hospital, NSW, Australia.
Compton
J S
JS
D000293:Adolescent; D000328:Adult; D000368:Aged; D002423:Cause of Death; D005260:Female; D015600:Glasgow Coma Scale; D006801:Humans; D007262:Infusions, Intravenous; D002532:Intracranial Aneurysm / Q000401:mortality / Q000601:surgery; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D009553:Nimodipine / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy / Q000401:mortality; D013345:Subarachnoid Hemorrhage / Q000401:mortality / Q000601:surgery
D009553:Nimodipine